- Claritas Pharmaceuticals ( CLAS) is expanding its R-107 development program to include the treatment of COVID-19 related sepsis
- Sepsis is the leading cause of death in COVID-19 patients
- Data suggests that R-107 significantly reduced mortality in an aggressive and clinically predictive animal model of sepsis
- Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
- Claritas Pharmaceuticals ( CLAS) opened trading at C$0.04 per share
Claritas Pharmaceuticals ( CLAS) is expanding its R-107 development program to include the treatment of COVID-19 related sepsis.
Sepsis is the leading cause of death in COVID-19 patients.
Most COVID-19 infections cause mild to moderate illness with respiratory and flu-like symptoms, including fever, chills, cough and sore throat. However, in a significant number of patients, the disease progresses from these initial mild symptoms to more serious and potentially fatal viral sepsis.
In COVID-19 viral sepsis, the body has a dysregulated immune response to the coronavirus, which causes severe oxidant stress and life-threatening dysfunction in organs including the lungs, brain, kidneys, heart, and liver. COVID-19 viral sepsis is the leading cause of death among COVID-19 infected patients, with a mortality rate in the range of 30% – 40%.
“The data we are announcing today demonstrate that R-107 significantly reduced mortality in an aggressive and clinically predictive animal model of sepsis. The importance of these data cannot be overstated,” said Robert Farrell, Claritas’ President and CEO.
“While bacterial sepsis may be treated with antibiotics, this is not the case with COVID-19 viral sepsis. Approved therapies, such as remdesivir, dexamethasone and bamlanivimab, are helpful for patients with mild illness but are not particularly effective in COVID-19 patients who have developed sepsis. For COVID-19 patients who have developed sepsis, there are few available therapies beyond supportive care.”
Mr. Farrell went on to state that,
“Our data unequivocally demonstrate that R-107 treatment reduced mortality in a controlled study in a large animal model of sepsis. We are aware of no other drug that is marketed or in development that has achieved superior results in this animal model of the disease.”
Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.
Claritas Pharmaceuticals ( CLAS) opened trading at C$0.04 per share.
